Table 1.
Clinical and epidemiological breakpoints, MIC50, MIC90, and frequency of resistance of the MRSA isolates.
| Antimicrobial | Clinical MIC Breakpoints [17] (mg/L) | Epidemiological MIC Breakpoints [17] (mg/L) (T) | MIC50 (mg/L) (n = 169) | MIC90 (mg/L) (n = 169) | % DS (N) |
|---|---|---|---|---|---|
| Cefoxitin (FOX) | 4 | NA | >16 | >16 | 100.0 (169) |
| Chloramphenicol (CHL) | 8 | NA | 16 | 64 | 27.2 (46) |
| Ciprofloxacin (CIP) | 1 | 1 | 0.5 | >8 | 33.1 (56) |
| Clindamycin (CLI) | 0.25 | 0.25 | >4 | >4 | 88.2 (149) |
| Erythromycin (ERY) | 2 | 1 | >8 | >8 | 61.5 (104) |
| Fusidic acid (FUS) | 1 | 0.5 | ≤0.5 | ≤0.5 | 1.8 (3) |
| Gentamicin (GEN) | 2 | (2) | ≤1 | ≤1 | 8.3 (14) |
| Kanamycin (KAN) | 8 | NA | ≤4 | 32 | 16.6 (28) |
| Linezolid (LZD) | 4 | 4 | 2 | 4 | 1.8 (3) |
| Mupirocin (MUP) | NA | (1) | ≤0.5 | ≤0.5 | 1.2 (2) |
| Penicillin (PEN) | 0.125 | NA | >2 | >2 | 100.0 (169) |
| Quinupristin/dalfopristin (SYN) | 2 | NA | 2 | 4 | 59.2 (100) |
| Rifampicin (RIF) | 0.06 | (0.03) | ≤0.016 | ≤0.016 | 0.6 (1) |
| Streptomycin (STR) | NA | NA | 8 | 16 | 9.5 (16) |
| Sulfamethoxazole (SMX) | NA | NA | ≤64 | ≤64 | 1.2 (2) |
| Tetracycline (TET) | 2 | 1 | >16 | >16 | 100.0 (169) |
| Tiamulin (TIA) | NA | NA | >4 | >4 | 79.9 (135) |
| Trimethoprim (TMP) | NA | (2) | ≤2 | >32 | 49.7 (84) |
| Vancomycin (VAN) | 2 | 2 | ≤1 | ≤1 | 0.0 (0) |
DS, Decreased susceptibility; NA, Not Applicable; (T), Tentative ECOFF; N, number of DS isolates.